<DOC>
	<DOCNO>NCT01331603</DOCNO>
	<brief_summary>Recently , demonstrate iron overload associate appearance labile plasma iron ( LPI ) . LPI redox active rapidly take cell , lead rise labile iron pool ( LIP ) catalyze generation reactive oxygen specie ( ROS ) , lead cellular damage . The LPI data mostly derive thalassemia iron overload research , however , data describe LPI correlation classical iron overload parameter ( ferritin , TSAT ) acute anemias MDS Therefore go assess LPI iron overload myelodysplastic syndrome ( MDS ) ( low high risk ) primary myelofibrosis , order ass whether use alternative routinely use parameter ; TSAT ferritin level .</brief_summary>
	<brief_title>Assessment Labile Plasma Iron ( LPI ) Myelodysplastic Syndromes ( MDS ) Primary Myelofibrosis</brief_title>
	<detailed_description>Approximately 60-80 % patient myelodysplastic syndrome ( MDS ) present symptomatic anemia 80-90 % , , require red blood cell ( RBC ) transfusion . Excess transfusional iron cause iron overload ( IO ) characterize elevate serum ferritin ( &gt; 1000ng/ml ) transferrin saturation ( TSAT &gt; 50 % ) level . Assessment IO use serum ferritin TSAT level accurate enough due change serum ferritin TSAT inflammatory condition . Since serum ferritin consider positive acute phase reactant therefore inflammatory state lead increase serum ferritin level reflect exact amount iron overload . In contrast TSAT decrease inflammation addition follow diurnal variations.The aim present study ass level LPI patient iron overload MDS patient ( low high risk ) , also patient primary myelofibrosis , order find laboratory correlation LPI , TSAT srum ferritin level . Methods : The study contain 50 patient low+high risk MDS patient patient primary myelofibrosis iron overload . The risk stratification patient calculate accord WPSS ( WHO adapt Prognostic Scoring System ) After ICF ( Informed Consent Form ) sign patient follow laboratory test take study : - Ferritin ( local laboratory ) - Transferrin Saturation ( local laboratory ) - CRP ( local laboratory ) - LPI ( feROSâ„¢ eLPI Aferrix Ltd. , Tel- Aviv , Israel )</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>age &gt; 18 year old MDS patient ( low high risk ) age &lt; 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>MDS</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>low+high risk MDS patient</keyword>
	<keyword>patient</keyword>
</DOC>